MicroPET assessment of androgenic control of @entity413 and XXXX uptake in the @entity35 prostate and a prostate cancer @entity5 model.

@entity1 @entity251 @entity263 @entity419 @entity0 @entity586 @entity5 @entity19 @entity587 @entity4743 @entity598 @entity342 @entity35 @entity18808 @entity4742 @entity413
PET has been used to monitor changes in @entity5 metabolism in @entity0 following hormonal therapy. This study was undertaken to determine whether PET imaging could evaluate early metabolic changes in @entity263 following @entity342 ablation therapy. Studies were performed comparing two positron-emitting tracers, @entity419 and @entity18808 , in Sprague-Dawley male @entity35 to monitor metabolic changes in normal prostate tissue. Additional studies were performed in @entity19 bearing the CWR22 @entity342 -dependent @entity1 @entity263 to evaluate metabolic changes in @entity263 . In @entity35 , for the @entity342 ablation pretreatment, 1 mg @entity4742 ( @entity4743 ) was injected subcutaneously 3 and 24 hours before tracer injection. For @entity342 pretreatment, 500 microg @entity586 ( @entity587 ) was injected intraperitoneally 2 and 6 hours before tracer injection. The @entity35 were divided into three groups, Group A (no- @entity4743 , no- @entity587 , n = 18), Group B ( @entity4743 , no- @entity587 , n = 18) and Group C ( @entity4743 , @entity587 , n = 18). In each group, 10 animals received @entity419 , whereas the remaining eight animals were administered @entity18808 . @entity35 were sacrificed at 120 min post-injection of @entity419 or 30 min post-injection of @entity18808 . Pretreatment of the @entity19 model using @entity587 (200 microg of @entity587 in 0.1 mL of sunflower seed oil) or @entity4743 (200 microg of @entity4743 in 0.1 mL of sunflower seed oil) was conducted every 2 days for one week. @entity19 were imaged with both tracers in the microPET scanner (Concorde Microsystems Inc.). @entity4743 treatment caused a decrease in @entity598 and @entity413 metabolism in the @entity35 prostate. Co-treatment with @entity587 maintained the @entity413 metabolism levels at baseline values. In the @entity5 bearing @entity19 , similar effects were seen in @entity419 study, while there was no significant difference in @entity18808 uptake. These results indicate that changes in serum @entity251 levels influence @entity419 uptake in the prostate gland, which is closely tied to @entity413 metabolism, within 24 hours of treatment and in the @entity263 within 1 week. These early metabolic changes could enable monitoring metabolic changes in @entity263 following treatment by imaging using @entity419 PET. Further studies are needed to clarify the reason for the insensitivity of @entity18808 for measuring metabolic change in @entity263 .
